13 Sept. 2012
WILMINGTON, N.C., and BERLIN, GERMANY, (September 13, 2012) - Pharmaceutical Product Development, LLC (PPD) and the Global Allergy and Asthma European Network e.V. (GA2LEN) today announced a strategic alliance in which GA2LEN will provide PPD access to the network's allergy and asthma experts and to more than 100 allergy and asthma sites in Europe.
In return, the alliance will enable GA2LEN to increase the amount of research it conducts in allergic diseases, as well as provide the network with earlier access to new medical therapies to help accelerate their development. The alliance enhances GA2LEN's role in providing health care treatment options for people affected by allergic diseases.
"This agreement supports our strategy to establish collaborations across a wide range of therapeutic areas," said Paul Colvin, executive vice president of global clinical development for PPD. "The large size of this network, coupled with its extensive scientific expertise, strengthens our capabilities as a full development respiratory partner by increasing our ability to recruit sites and patients into allergy and asthma trials."
PPD and GA2LEN will work to reduce allergy and asthma study start-up times, increase the number of patients recruited for clinical trials, and ensure the availability of resources and training to increase the number of physicians and support staff conducting research.
"Allergies and asthma are Europe's most common chronic diseases, and their prevalence is growing," said Professor Torsten Zuberbier, secretary general for GA2LEN. "As a consortium of more than 100 leading European partners and multidisciplinary research centers specializing in allergic diseases, we conduct wide-ranging studies across Europe involving patients who face varying environmental and lifestyle impacts. This alliance with PPD builds our reputation as a leader in allergy and asthma treatment, as we will better understand the evolution and development of allergic diseases and how to treat them more effectively."
GA2LEN is a multidisciplinary research network addressing all aspects of allergic diseases with a view to reducing the burden of allergy and asthma. GA2LEN aims to enhance the quality and relevance of European research and disseminate best practice and knowledge to health professionals, patients and policy makers. Understanding factors and mechanisms of allergic diseases will contribute to developing better health care and improving the quality of life of more than 80 million Europeans with allergies.